More Red Flags for Valeant; Berkshire Battles Headwinds
Shares the beleaguered pharma firm may look cheap, but investors should remain very cautious. Meanwhile, Berkshire pulls off decent results under less-than-ideal circumstances.
Jason Stipp: I'm Jason Stipp for Morningstar. Welcome to The Friday Five, Morningstar's take on five stories in the market this week.
Joining me with The Friday Five is Morningstar markets editor Jeremy Glaser.
Jason Stipp does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.